Silence Therapeutics plc (SLN) fair value analysis
Nasdaq · Updated 2026-10-19
SLN price how computed
Valuation status
No fair-value estimate yetSLN has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for SLN yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $8.68
- Sector
- Healthcare
- 12-month range
- $4.30–$15.43
- Market cap
- $539M
- From 52-week high
- -43.7%
- Shares outstanding
- 62.2M
- Rank in Healthcare by quality score
- #213 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Silence Therapeutics plc is a biopharmaceutical company that develops RNA interference therapies designed to treat rare genetic and other diseases. The company is headquartered in the United Kingdom and operates as a Nasdaq-listed entity within the Healthcare sector.
SLN currently ranks #213 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $539M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $614K
- Net margin
- -9759.2%
- EPS (TTM)
- $-1.01
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- -33.3%
- Shares outstanding
- 62.2M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 19 · oversold
- 50-day average
- $12.31
- 200-day average
- $8.36
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+18.8%)
2026-03 ▼ miss (-44.4%)
2025-12 ▲ beat (+44.9%)
2025-09 ▲ beat (+28.6%)
2025-06 ▼ miss (-100.0%)
2025-03 ▼ miss (-46.3%)
2024-12 ▲ beat (+169.3%)
2024-09 ▼ miss (-461.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 0 hold · 1 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $33
- Target vs last price
- +280.2%
What our data shows for SLN
- Shares are trading in the middle of their 12-month price range of $4.30–$15.43.
- The 14-day relative strength index sits at an oversold 19.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- SLN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the SLN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is SLN stock undervalued?
TickrTrends has no fair-value estimate for SLN yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is SLN's TickrTrends verdict?
SLN is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does SLN compare to other Healthcare stocks?
SLN ranks #213 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is SLN overbought or oversold?
SLN's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does SLN report earnings next?
SLN's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does SLN usually beat earnings estimates?
Over its last 8 reported quarters SLN beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SLN?
Of 7 analysts covering SLN, 6 rate it a buy, 0 a hold and 1 a sell - buy-leaning, with a consensus price target of $33 (+280.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.